ID   NCI-H1299
AC   CVCL_0060
SY   H1299; H-1299; NCIH1299
DR   BTO; BTO:0002552
DR   CLO; CLO_0007986
DR   EFO; EFO_0003043
DR   MCCL; MCC:0000352
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5803
DR   BCRJ; 0185
DR   BioGRID_ORCS_Cell_line; 234
DR   BioSample; SAMN03471642
DR   BioSample; SAMN03471739
DR   BioSample; SAMN10988385
DR   cancercelllines; CVCL_0060
DR   CCRID; 1101HUM-PUMC000469
DR   CCRID; 1102HUM-NIFDC00050
DR   CCRID; 3101HUMSCSP589
DR   CCRID; 3101HUMTCHu160
DR   CCRID; 4201HUM-CCTCC00640
DR   Cell_Model_Passport; SIDM00649
DR   ChEMBL-Cells; CHEMBL3308501
DR   ChEMBL-Targets; CHEMBL612255
DR   CLS; 300485
DR   Cosmic; 722069
DR   Cosmic; 724831
DR   Cosmic; 877265
DR   Cosmic; 877418
DR   Cosmic; 903585
DR   Cosmic; 961838
DR   Cosmic; 980971
DR   Cosmic; 1004693
DR   Cosmic; 1032443
DR   Cosmic; 1047106
DR   Cosmic; 1066159
DR   Cosmic; 1146875
DR   Cosmic; 1154606
DR   Cosmic; 1175867
DR   Cosmic; 1218870
DR   Cosmic; 1239925
DR   Cosmic; 1609524
DR   Cosmic; 1870264
DR   Cosmic; 1925845
DR   Cosmic; 1995520
DR   Cosmic; 2042873
DR   Cosmic; 2125178
DR   Cosmic; 2630419
DR   Cosmic; 2664126
DR   Cosmic; 2749161
DR   Cosmic; 2772159
DR   Cosmic-CLP; 724831
DR   DepMap; ACH-000510
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 724831
DR   GEO; GSM108807
DR   GEO; GSM108808
DR   GEO; GSM185871
DR   GEO; GSM206471
DR   GEO; GSM253382
DR   GEO; GSM274743
DR   GEO; GSM274744
DR   GEO; GSM353229
DR   GEO; GSM434266
DR   GEO; GSM784253
DR   GEO; GSM794311
DR   GEO; GSM827467
DR   GEO; GSM844617
DR   GEO; GSM887355
DR   GEO; GSM888433
DR   GEO; GSM1374698
DR   GEO; GSM1374699
DR   GEO; GSM1670165
DR   IARC_TP53; 21537
DR   IARC_TP53; 21722
DR   IGRhCellID; H1299GEO
DR   KCLB; 25803
DR   KCLB; 91299
DR   LiGeA; CCLE_300
DR   LINCS_LDP; LCL-1609
DR   Lonza; 796
DR   MetaboLights; MTBLS873
DR   NCI-DTP; NCI-H1299
DR   PharmacoDB; NCIH1299_1006_2019
DR   PRIDE; PXD003743
DR   PRIDE; PXD005291
DR   PRIDE; PXD018581
DR   PRIDE; PXD030304
DR   PRIDE; PXD035746
DR   Progenetix; CVCL_0060
DR   PubChem_Cell_line; CVCL_0060
DR   TOKU-E; 2592
DR   TOKU-E; 3620
DR   Ubigene; YC-D010
DR   Wikidata; Q5628772
RX   PubMed=1311061;
RX   PubMed=1563005;
RX   PubMed=1565469;
RX   PubMed=8806092;
RX   PubMed=11030152;
RX   PubMed=12068308;
RX   PubMed=17332333;
RX   PubMed=18083107;
RX   PubMed=19153074;
RX   PubMed=19472407;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=20679594;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=24335698;
RX   PubMed=25485619;
RX   PubMed=25714623;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26589293;
RX   PubMed=26929325;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29444439;
RX   PubMed=29681454;
RX   PubMed=30038707;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=34737324;
RX   PubMed=35839778;
RX   PubMed=36264037;
WW   https://en.wikipedia.org/wiki/H1299
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-15.html
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-173.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 30 hours (PubMed=25984343); 22.5 hours (PubMed=29681454).
CC   HLA typing: A*24:02,32:01; B*40:02,40:02; C*02:02,02:02; DRB1*01:01,01:01 (PubMed=26589293).
CC   HLA typing: A*24:02,32:01:01; B*40:01,40:02:01; C*03:03:01,02:02:02 (PubMed=26929325).
CC   Karyotypic information: Has lost chromosome Y (PubMed=25714623).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=20557307; ATCC).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=1311061; PubMed=12068308; ATCC; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.33%; Native American=0%; East Asian, North=2.13%; East Asian, South=0%; South Asian=0%; European, North=62.86%; European, South=34.68% (PubMed=30894373).
CC   Misspelling: HI299; Note=Occasionally.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=20679594; PubMed=24335698; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D10S1248: 13,17
ST   D12S391: 21
ST   D13S317: 12
ST   D16S539: 12,13
ST   D18S51: 16
ST   D19S433: 14
ST   D1S1656: 12,15
ST   D21S11: 32.2
ST   D22S1045: 15,16
ST   D2S1338: 23,24
ST   D2S441: 11,13
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 10
ST   D8S1179: 10,13
ST   FGA: 20
ST   Penta D: 13
ST   Penta E: 11
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,17,18 (ATCC; CCRID)
ST   vWA: 16,18 (Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=20679594; PubMed=24335698; PubMed=25877200)
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 45
//
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D.,
RA   Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
//
RX   PubMed=1563005;
RA   Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.;
RT   "Neuromedin B is present in lung cancer cell lines.";
RL   Cancer Res. 52:2732s-2736s(1992).
//
RX   PubMed=1565469;
RA   Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P.,
RA   Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F.,
RA   Linnoila R.I.;
RT   "Expression of mutant p53 proteins in lung cancer correlates with the
RT   class of p53 gene mutation.";
RL   Oncogene 7:743-749(1992).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339;
RA   Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T.,
RA   Takada M., Fukuoka M., Nakagawa K.;
RT   "Differential constitutive activation of the epidermal growth factor
RT   receptor in non-small cell lung cancer cells bearing EGFR gene
RT   mutation and amplification.";
RL   Cancer Res. 67:2046-2053(2007).
//
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H.,
RA   Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P.,
RA   Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q.,
RA   Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
//
RX   PubMed=19153074; DOI=10.1093/hmg/ddp034;
RA   Medina P.P., Castillo S.D., Blanco S., Sanz-Garcia M., Largo C.,
RA   Alvarez S., Yokota J., Gonzalez-Neira A., Benitez J., Clevers H.C.,
RA   Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.;
RT   "The SRY-HMG box gene, SOX4, is a target of gene amplification at
RT   chromosome 6p in lung cancer.";
RL   Hum. Mol. Genet. 18:1343-1352(2009).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=24335698; DOI=10.1093/neuonc/not202;
RA   An Q., Fillmore H.L., Vouri M., Pilkington G.J.;
RT   "Brain tumor cell line authentication, an efficient alternative to
RT   capillary electrophoresis by using a microfluidics-based system.";
RL   Neuro-oncol. 16:265-273(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25714623; DOI=10.1371/journal.pone.0116218;
RA   Liang-Chu M.M.Y., Yu M.-M., Haverty P.M., Koeman J., Ziegle J., Lee M.,
RA   Bourgon R., Neve R.M.;
RT   "Human biosample authentication using the high-throughput,
RT   cost-effective SNPtrace(TM) system.";
RL   PLoS ONE 10:E0116218-E0116218(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26929325; DOI=10.1073/pnas.1521812113;
RA   Tripathi S.C., Peters H.L., Taguchi A., Katayama H., Wang H.,
RA   Momin A., Jolly M.K., Celiktas M., Rodriguez-Canales J., Liu H.,
RA   Behrens C., Wistuba I.I., Ben-Jacob E., Levine H., Molldrem J.J.,
RA   Hanash S.M., Ostrin E.J.;
RT   "Immunoproteasome deficiency is a feature of non-small cell lung
RT   cancer with a mesenchymal phenotype and is associated with a poor
RT   outcome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:E1555-E1564(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=30038707; DOI=10.18632/oncotarget.25642;
RA   Du L.-Q., Zhao Z.-Z., Suraokar M.B., Shelton S.S., Ma X.-Y., Hsiao T.-H.,
RA   Minna J.D., Wistuba I.I., Pertsemlidis A.;
RT   "LMO1 functions as an oncogene by regulating TTK expression and
RT   correlates with neuroendocrine differentiation of lung cancer.";
RL   Oncotarget 9:29601-29618(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=34737324; DOI=10.1038/s41598-021-00779-5;
RA   Lung O., Candlish R.C., Nebroski M., Kruckiewicz P., Buchanan C.,
RA   Moniwa M.;
RT   "High-throughput sequencing for species authentication and
RT   contamination detection of 63 cell lines.";
RL   Sci. Rep. 11:21657-21657(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=36264037; DOI=10.1002/psc.3458;
RA   Albrecht C.J., Stumpf F.M., Kruger L., Niedermeier M.L., Stengel F.,
RA   Marx A.;
RT   "Chemical proteomics reveals interactors of the alarmone diadenosine
RT   triphosphate in the cancer cell line H1299.";
RL   J. Pept. Sci. 29:e3458.1-e3458.10(2023).
//